Lan, B.; Zeng, S.; Zhang, S.; Ren, X.; Xing, Y.; Kutschick, I.; Pfeffer, S.; Frey, B.; Britzen-Laurent, N.; Grützmann, R.;
et al. Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. Cancers 2025, 17, 3181.
https://doi.org/10.3390/cancers17193181
AMA Style
Lan B, Zeng S, Zhang S, Ren X, Xing Y, Kutschick I, Pfeffer S, Frey B, Britzen-Laurent N, Grützmann R,
et al. Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. Cancers. 2025; 17(19):3181.
https://doi.org/10.3390/cancers17193181
Chicago/Turabian Style
Lan, Bin, Siyuan Zeng, Shuman Zhang, Xiaofan Ren, Yuming Xing, Isabella Kutschick, Susanne Pfeffer, Benjamin Frey, Nathalie Britzen-Laurent, Robert Grützmann,
and et al. 2025. "Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326" Cancers 17, no. 19: 3181.
https://doi.org/10.3390/cancers17193181
APA Style
Lan, B., Zeng, S., Zhang, S., Ren, X., Xing, Y., Kutschick, I., Pfeffer, S., Frey, B., Britzen-Laurent, N., Grützmann, R., Cordes, N., & Pilarsky, C.
(2025). Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. Cancers, 17(19), 3181.
https://doi.org/10.3390/cancers17193181
